A detailed history of Farrow Financial Inc. transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Farrow Financial Inc. holds 11,500 shares of LCTX stock, worth $6,900. This represents 0.01% of its overall portfolio holdings.

Number of Shares
11,500
Previous 11,500 -0.0%
Holding current value
$6,900
Previous $11.5 Million 9.22%
% of portfolio
0.01%
Previous 0.01%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 02, 2024

SELL
$0.86 - $1.48 $4,730 - $8,140
-5,500 Reduced 32.35%
11,500 $17 Million
Q4 2023

Feb 08, 2024

BUY
$0.91 - $1.35 $15,470 - $22,950
17,000 New
17,000 $18.5 Million

Others Institutions Holding LCTX

About Lineage Cell Therapeutics, Inc.


  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $102M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track Farrow Financial Inc. Portfolio

Follow Farrow Financial Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Farrow Financial Inc., based on Form 13F filings with the SEC.

News

Stay updated on Farrow Financial Inc. with notifications on news.